Introduction
Glomerulosclerosis, characterized by a phenotype transition of mesangial cells and an increase in extracellular matrix formation\cite{1, 2, 3}, is a final common pathway leading to the loss of renal function in a variety of underlying kidney diseases. Multiple injuries to the glomerulus stimulate the glomerular intrinsic cells to proliferate, secrete pro-inflammatory factors, undergo cell death or necrosis, and lay down extracellular matrix\cite{3}.

TGF-β, known as a pivotal driver of glomerulosclerosis and tubulointerstitial fibrosis, is a multifunctional cytokine that regulates cell proliferation, differentiation, and production of extracellular matrix proteins in a variety of cells including mesangial cells\cite{4}. Many different cellular responses are elicited by TGF-β, and these are often cell-type specific\cite{5}. The classic cellular response pathway involves Smad-mediated changes in target gene transcription, which have become well understood in the past few years. Other signaling pathways, including mitogen activated protein (MAP) kinases, PI3 kinases, and Rho-like GTPases, can modulate Smad-dependent or independent cellular responses\cite{6, 7}. In particular, it has been proven that TGF-β also mediates protein kinase A (PKA) signal transduction \textit{in vivo}\cite{8}. After TGF-β combines with its receptor, the receptor phosphorylates PKA directly, with the formation of complexes between Smads and the regulatory subunits of PKA. Inhibition of the PKA signal pathway could block the matrix protein synthesis stimulated by TGF-β \textit{in vitro}\cite{9}.

Multiple drugs with different pharmacological profiles are employed in the experiments on glomerulosclerosis, because it is one of the major pathological features of primary glomerular diseases. The more recently introduced drugs include the peroxisome proliferator-activated receptor (PPAR)γ agonists (thiazolidinediones or glitazones).

PPARγ, a nuclear receptor that regulates specific gene transcription\cite{10} is involved in the regulation of lipid and glucose metabolism\cite{11}, and inflammatory responses\cite{12}. Through PPARγ activation, PPARγ agonists exert some beneficial effects on different renal diseases, such as anti-
inflammatory effects\textsuperscript{[13]}, anti-fibrotic effects\textsuperscript{[14]}, and vascular protective effects\textsuperscript{[15]}, although the exact mechanism is not well understood\textsuperscript{[16]}. Recently, it has been reported that the promoter activity and phosphorylation levels of cyclic AMP responsive element binding protein (CREB) could be inhibited by the activation of PPAR\textgamma, although it is still unclear what the exact regulation mechanism is and whether additional regulation exists at the level of PPAR\textgamma Ser133 phosphorylation. Because CREB phosphorylation is mainly modulated through PKA activation, similar modulation effects are also performed by the PPAR\textgamma agonist, raising the possibility that PPAR\textgamma activation might mediate the PKA signal pathway. These observations allow the speculation that a probable direct modulation on PKA signaling by PPAR\textgamma exists in the complex cellular signal networks. Therefore, the interaction between PPAR\textgamma and PKA signaling was examined. The probable mechanisms of anti-glomerulosclerosis effects mediated by PPAR\textgamma agonist in mesangial cells (MCs) were also investigated \textit{in vivo}. On the other hand, telmisartan, a subclass of angiotensin receptor blockers (ARBs), has been reported to associate with PPAR\textgamma as a partial agonist\textsuperscript{[17]}. Therefore, we chose both troglitazone and telmisartan as PPAR\textgamma ligands for these experiments.

**Materials and methods**

**Reagents**

Recombinant TGF-\(\beta\), was purchased from R&D Systems (Minneapolis, MN). Telmisartan was obtained from Boehringer Ingelheim (Ingelheim, Germany). Troglitazone, a selective ligand for PPAR\textgamma, was kindly provided by Dr Ming HAN (Sankyo, Tokyo, Japan). Telmisartan and troglitazone were dissolved in DMSO, with a final concentration of 0.05% in the culture medium. Polyclonal anti-PPAR\textgamma (sc-7196) and anti-collagen IV (sc-9301) were purchased from Santa Cruz Biotechnology (California, USA). Monoclonal antibodies against CRE binding protein (CREB, \#9197) and phospho-CREB (\#9198), which recognizes phosphorylated Ser133, were obtained from Cell Signaling Technology (Boston, USA). Monoclonal anti-alphalpha smooth muscle actin (\(\alpha\)-SMA, ab32575) was obtained from Abcam (Cambridge, UK), and horseradish peroxidase (HRP)-conjugated anti-mouse, anti-rabbit immunoglobulin were obtained from Dako (Glostrup, Denmark). The ECL detection system was obtained from Pierce Biotechnology (Rockford, USA). GW9662, a specific PPAR\textgamma antagonist, was from Cayman chemical (Michigan, USA). H89, a selective inhibitor of PKA, was from Alexis Biochemicals (San Diego, USA).

**Cell culture**

Rat intraglomerular mesangial cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (GIBCO, USA), at 37 °C in 95% air / 5% CO\textsubscript{2}. Throughout this study, cells from passages 5 to 15 were used. All treatments were done in a serum-free medium in confluent cells that had been cultured in medium without FBS for 24 h before stimulation.

**Transient transfection and luciferase assay**

To assess the PPAR\textgamma activation, MCs at 80% confluence were transiently transfected with 2.0 \(\mu\)g of luciferase reporter plasmids containing either three consensus PPAR\textgamma response elements (pTAL-3xPPRE-TK-Luc) or the corresponding empty vector (pTAL-Luc) (a kind gift from Dr Qiu-jun LÜ) along with a \(\beta\)-galactosidase vector (Promega) for 4 h using Lipofectamine (Invitrogen Life Technologies, USA). The PPREx3-Luc reporter plasmid was designed to contain PPRE sites (5’-GTC-GACAGGGGACCAGGACAAAGGTCACGTTCGGGAGG TCAC-3’, three copies) attached to a luciferase vector (pTAL-Luc) as described\textsuperscript{[18]}. After a 16-h recovery period in serum-free medium, cells were treated with troglitazone or telmisartan. The transfections were done in triplicate and repeated at least three times to ensure the reproducibility of the results. Firefly luminescence and \(\beta\)-galactosidase values were measured in cell lysates according to the instructions of the manufacturer from Promega. PPRE activities were expressed as the ratio of relative light units to the \(\beta\)-galactosidase values. In all cases, the luciferase activity of the empty vectors was negligible. Results (mean±SD) were expressed as the fold increase in relative luciferase units, corrected to \(\beta\)-galactosidase, and compared with unstimulated cultures.

**Western blotting**

After being intervened with troglitazone or telmisartan, washed cells (PBS, 4 °C) were harvested under non-denaturing conditions (4 °C/30 min) with lysis buffer (50 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, 1% TritonX-100, 0.1% SDS, 1% NP-40, 0.5% deoxysodium cholate, 1 mmol/L EGTA, 0.5 mmol/L benzamidine, 1.5 mmol/L sodium fluoride, 30 \(\mu\)mol/L sodium vanadate, 10 \(\mu\)mol/L sodium pyrophosphate, 2 mmol/L PMSF, 10 \(\mu\)g/mL aprotinin, 10 \(\mu\)g/mL leupeptin). Proteins were separated by electrophoresis (10% sodium dodecyl sulfate-polyacrylamide gel) and electroblotted to a nitrocellulose membrane (Schleicher and Schuell, Keene, NH). The membranes were blocked with 5% nonfat dry milk in TBST (25 mmol/L Tris, 140 mmol/L NaCl, 3 mmol/L KCl, 0.05% Tween-20, pH 8.0, 37 °C, 1 h), and then were incubated with anti-PPAR\textgamma (1:200 dilution), anti-CREB (1:200 dilution), anti-pCREB (1:200 dilution), anti-\(\alpha\)-SMA (1:200 dilution), and anti-collagen IV (1:100 dilution) antibodies at 4 °C overnight with continuous shaking in TBST containing 5% nonfat dry milk. Membranes were then washed with TBST (10 min×3 times) and were incubated with appropriate horseradish peroxidase-conjugated secondary antibodies (1:1000 dilution) at room temperature for 1 h. Appropriate bands were identified with ECL Chemiluminescence Reagent and were followed by exposure to X-ray film (X-OMAT, Kodak, USA). Subsequently, immune complexes were removed from the membrane (5% NaOH, 37 °C, 5 min). Then, the immune complexes were re-blocked with 5% non-fat milk (37 °C, 1 h). Protein was assessed by re-blotting with anti-actin antibody (1:200 dilution) and a horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:1000 dilution). The bands were
photographed using Chemilumager 5500 (Alpha Innotech, San Leandro, CA).

**In vitro kinase assay for PKA activity**

After treatment with TGF-β1, troglitazone, telmisartan, or H89 for the indicated time periods, the cells were washed with ice-cold PBS and were harvested on ice. Then, cells were suspended in 0.5 mL of cold PKA extraction buffer (25 mmol/L Tris-HCl, pH 7.4, 0.5 mmol/L EDTA, 0.5 mmol/L EGTA, 10 mmol/L β-mercaptoethanol, 1 µg/mL leupeptin, 1 µg/mL aprotinin) and homogenized using a cold homogenizer. The supernatant was mixed with other compositions after centrifugation (5 min, 4 °C, 14,000 r/min). Subsequently, all reaction components were added on ice in a final volume of 25 µL of the following mixture: PKA Reaction 5×Buffer 5 µL, A1 Peptide (0.4 µg/µL) 5 µL, PKA Activator 5×Solution 5 µL, Peptide Protection Solution 1 µL, cAMP-Dependent Protein Kinase (2 µg/mL in PKA dilution buffer) 5 µL. The mixture was incubated for 30 min at room temperature. Then, the reaction was stopped by heating at 95 °C for 10 min, and the samples were loaded onto the agarose gel (0.8% agarose in 50 mmol/L Tris–HCl, pH 8.0) for electrophoresis. The phosphorylated peptide migrates towards the negative electrode (cathode) while the non-phosphorylated one migrates toward the positive electrode (anode). The negative control lacks PKA enzyme and contains only buffer, while only the positive control contains the PKA catalytic subunit (final concentration 16 U/mL) supplied with the kit. The intensity of the bands was quantified as above.

**Confocal microscopy**

Extracellular matrix accumulation and the p-CREB translocation into the nucleus were determined using confocal microscopy of monolayers stained with antibodies to collagen IV and p-CREB. The cells were plated in a chamber-slide for 24 h in regular medium and 24 h in serum-free medium. Accompanied with TGF-β1 stimulation, treatments with troglitazone, telmisartan, or H89 were applied for 24 h. This was followed by thorough washes with PBS. Then, the cells were fixed with 4% fresh paraformaldehyde at 4 °C for 30 min and were permeabilized in PBS containing 0.2% TritonX-100. To block the nonspecific reaction, the cells were incubated with 5% BSA in PBS for 60 min. Then, the cells were incubated with the specific primary antibodies against collagen IV at a dilution of 1:50 at 4 °C overnight. After washes, cells were incubated with FITC conjugated donkey anti-goat IgG (1:50) for 1 h in the dark at room temperature. Cells were double stained with PI (propidium iodide) to visualize the nuclei. Slides were washed three times with PBS and glass coverslips were applied after the addition of one drop of mounting media. Confocal microscopy was performed using a Zeiss confocal laser scanning microscope (Carl Zeiss, Inc, Thornwood, NY). Basal and apical membrane locations were determined visually in the Z-plane using light field microscopy. Two to three photomicrographs per monolayer at the basal and apical membranes were then scanned with an omnichrome laser filtered at 480 nm to detect FITC and 530 nm to detect PI.

**Statistical analyses**

Data were expressed as mean±SD. Difference of means was compared by one-way ANOVA and Student-Newman-Keuls *post hoc* test for the comparison of multiple means using SPSS 13.0 software. Statistical significance was defined as *P*<0.05.

**Results**

PPARγ ligands enhanced activity of PPARγ response elements (PPRE) in MCs

As shown in Figure 1, treatment with different concentrations of PPARγ agonist caused an effective activation of promoter plasmid. The differences of luciferase levels between the treatment group and the control group were statistically significant. Both troglitazone and telmisartan enhanced luciferase expression in a dose-dependent manner. Figure 1C shows the time course of the effects of 5 µmol/L troglitazone or 10 µmol/L telmisartan on PPRE activities. The PPARγ activation was detected as early as 12 h after the start of incubation, and

![Figure 1](image_url)

**Figure 1.** Both troglitazone and telmisartan activated PPARγ response elements (PPRE) effectively. MCs were transfected with 2.0 µg tk-PPREx3-Luc and 0.2 µg β-galactosidase vectors. After transfection, cells were treated with 1, 2.5, 5 µmol/L troglitazone (A) or 0.1, 1, and 10 µmol/L telmisartan (B) for 24 h. Meanwhile, transfected cells were treated with 5 µmol/L troglitazone or 10 µmol/L telmisartan for the indicated periods of time (C). Luciferase and β-galactosidase assays were performed at least three times, and the results were expressed as percentage of control considering the values in untreated samples as 100%. Luciferase activity represents data that have been normalized with β-galactosidase activity. The data represent the mean±SD of three independent experiments. *b*P<0.05 vs the un-stimulated controls.
enhanced remarkably in 24 h after treatments. Both troglitazone and telmisartan enhanced luciferase expression in a time-dependent manner.

The suppression on PKA signaling induced by PPARγ agonists in normal MCs

To elucidate whether the influence on PKA pathway by PPARγ agonist existed in MCs, we measured the expression of major proteins of the PKA signal pathway. The inhibition of PKA activity was accelerated between 12 and 24 h after troglitazone or telmisartan exposure and then performed moderately. Meanwhile, both troglitazone and telmisartan inhibited PKA activation in variety of concentrations (Figure 2). Because the CREB phosphorylation depends on the PKA activation, we extended our observations by measuring the pCREB expression levels in response to the PPARγ agonist. Accordingly, significant pCREB signals at Ser-133 were detected within 24 h of stimulation by troglitazone or telmisartan (Figure 3A). The pCREB expression was suppressed markedly after exposure to either troglitazone or telmisartan. The inhibition of pCREB stimulated by PPARγ agonist could be abolished by a specific PPARγ antagonist-GW9662 (Figure 3B). However, PPARγ agonist had little effect on the total CREB expression (Figure 3). These findings indicated that PPARγ activation could directly influence the activation of PKA/CREB signaling in normal mesangial cells.

Inhibition of TGF-β1-PKA signaling by PPARγ agonists

Because CREB cooperates with Smads to mediate TGF-β1-induced glomerulosclerosis process, we tested whether the PKA signal pathway, under the influence of TGF-β1, was suppressed by PPARγ agonist. In harmony with the former results, PPARγ agonist remarkably suppressed PKA activation induced by TGF-β1 (Figure 4A). pCREB expression was also suppressed after PPARγ agonist treatments (Figure 4B), which was recovered by GW9662 (Figure 4B). We also examined the inhibition effects on PKA signaling performed by H89, a selective inhibitor of PKA. The mimetic effects were also obtained after pre-incubation with 10 μmol/L H89 (Figure 4C, 4D). Similar results were also obtained by confocal microscopy assays. It is demonstrated that a visible expression of pCREB in TGF-β1-treated MCs (Figure 4F) and noticeable suppression in PPARγ agonist-treated (Figure 4G) and H89-treated MCs compared with control (Figure 4E).

PPARγ agonists suppressed TGF-β1-induced MCs phenotype alteration

The induction of α-SMA is a hallmark for MCs phenotype alteration in glomerulosclerosis process. As shown in Figure 5, both troglitazone and telmisartan dramatically suppressed the α-SMA expression mediated by TGF-β1. The suppression effects performed by PPARγ agonists were abolished by GW9662 pre-incubation.

PPARγ agonists inhibit TGF-β1-mediated collagen IV expression

ECM accumulation is a dynamic process that results from the delicate balance between matrix synthesis and degradation. The collagen VI distribution, which was characterized as the important component of ECM[19], was shown by confocal microscopy. As shown in Figure 6, TGF-β1 markedly induced collagen IV expression in the extracellular matrix. Either telmisartan or troglitazone significantly abolished collagen IV overproduction stimulated by TGF-β1 (Figure 6A). In harmony with immunoblotting, similar results were obtained when the MCs were stained with a specific antibody against collagen IV (Figure 6B–6F). The collagen IV over-expression induced by TGF-β1 was notably reduced after both PPARγ agonists and H89 treatments.

Figure 2. PPARγ agonists inhibited PKA signaling in normal MCs. (A) Time course 1. MCs were treated with troglitazone (Tro, 5 μmol/L) for the indicated time periods, and PKA activity was measured by PepTag® Non-Radioactive Protein Kinase Assays (promega) as described. Purified PKA catalytic subunit was used as a positive control (negative control contained only buffer), while all other samples contain cell lysates from treated and untreated cells. (B) Time course 2. Telmisartan (Tel, 10 μmol/L). PKA activity was estimated as in (A). (C) Dose response 1. MCs were treated with troglitazone (1, 2.5, and 5 μmol/L) for 24 h. (D) Dose response 2. Telmisartan (0, 0.1, 1, and 10 μmol/L, 24 h).
Discussion

PPARγ is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. Like other nuclear receptors, PPARγ has a modular structure consisting of an agonist-dependent activation domain (AF-2), a DNA binding domain, and an agonist-independent activation domain (AF-1). Many of its biological effects are mediated by receptor regulation of target gene transcription in a ligand-dependent manner. It has been recognized increasingly that PPARγ agonists have protective effects on the progression of glomerulosclerosis, possibly by a mechanism that is independent of insulin/glucose effects and associated with the regulation of glomerular cell proliferation, hypertrophy, and decreased PAI-1 and TGF-β expression. Through a PPARγ-dependent manner, PPARγ agonists exert some beneficial effects on the kidney, although the molecular mechanism is not well understood.

In this paper, we demonstrated that both troglitazone and telmisartan suppressed PKA signal transduction in both dose-dependent and time-dependent manners in normal MCs. Pre-incubation with GW9662 abolished the suppression effects induced by both troglitazone and telmisartan, suggesting that the suppression effects were caused by PPARγ activation. It suggest that PPARγ agonists indeed influenced PKA signaling cascades in MCs by PPARγ dependent mechanisms.

The inactive holoenzyme PKA consists of two regulatory (R) and two catalytic subunits. Unlike many protein kinases whose activity is regulated by the transient addition of a phosphate to the activation loop, PKA is assembled as a fully active enzyme that is kept in its inactive state by inhibitory proteins. There are two classes of inhibitors: the heat-stable protein kinase inhibitors (PKIs) and the regulatory subunit. PKI binds with high affinity to the free catalytic subunit, but, unlike the R subunit, it includes a nuclear export signal (NES) that mediates active nuclear export of the catalytic subunit. The NES at the C terminus of the PKI provides a mechanism for rapidly exporting the catalytic subunit from the nucleus. Protein-protein interactions are important for many signaling processes. The research focused on PPARγ localizations disclosed the protein-protein interactions between PPARγ and MEKs in its nuclear translocation. Indeed, several nuclear receptors were reported to interact with regulatory proteins via the AF2 domain of PPARγ, including glucocorticoid receptors, estrogen receptors, and NF-kB interactions with...
PPARγ[26]. How did PPARγ affect the PKA activities? One speculation is, through nuclear export processes of catalytic subunits, an interaction may exist in the protein complexes of the catalytic subunit and PKI caused by PPARγ. Whether the protein-protein interaction indeed exists between PPARγ and the catalytic subunit, and how it works, are questions that require further research.

As a multi-functional factor, TGF-β is a pivotal driver of glomerulosclerosis and tubulointerstitial fibrosis. The classical TGF-β/Smads pathway in the fibrotic process has been well illustrated[27]. In recent years, some signaling molecules other than Smads were found to be involved in TGF-β signaling. For example, p38 MAPK was previously recognized to play a critical role in the apoptosis of AML-12 cells induced by TGF-β[28]. Additionally, interactions between the TGF-β/Smads pathway components with the PKA/CREB signal pathway have been widely reported[29, 30]. The phosphorylation of Smad3 and Smad4 by TGF-β have a direct protein-protein interaction with the regulatory subunit of PKA, leading to the release of the PKA catalytic subunit from the regulator subunit. When the PKA catalytic subunit translocates into the nucleus to phosphorylate its cellular substrate (CREB), the pCREB binds to conserved CREs in the promoters of many cAMP-responsive genes and regulates related gene transcription.

TGF-β/PKA signaling plays an important role in many aspects of physiologic and pathologic processes. For example, TGF-β induced apoptosis and Epithelial-to-Mesenchymal Transition (EMT) in AML-12 murine hepatocytes was associated with PKA activation[31]. Singh et al reported that laminin and fibronectin (Fn) expression induced by TGF-β1 could be down-regulated by PKA signaling blockage; however, the inhibition of PKC did not have significant effects on TGF-β1
mediated laminin synthesis. With these observations, it was also reported that the secretion of Fn was downregulated by PPARγ activation in lung carcinoma cells, which was mediated by antagonizing the transactivating activity of CREB binding to one CRE site in the Fn promoter. These results indicate a potential involvement of PKA signaling in TGF-β mediated pro-glomerulosclerosis process.

In our study, we proved that PPARγ agonists remarkably suppressed the PKA signaling stimulated by TGF-β1. The suppression effects were dependent on PPARγ activation. These results suggest that the suppression of PKA signaling cascades induced by PPARγ agonists not only in normal MCs, but also in TGF-β stimulated cells. Because of the tight interaction between TGF-β and the PKA/CREB pathway, which is important for the glomerulosclerosis process, these observations provided possibilities that PPARγ agonists might inhibit the TGF-β mediated glomerulosclerosis process through the suppression of the PKA pathway.

Furthermore, the inhibition of TGF-β/PKA signaling enacted by the PPARγ agonists efficiently blocked the αSMA expression and collagen IV accumulation. The results demonstrate that TGF-β1 itself could stimulate MCs to differentiate into myofibroblasts; and that treatment with PPARγ agonists, accompanied by TGF-β1-stimulated differentiation, could inhibit the differentiation of MCs. Moreover, the inhibition effects of both telmisartan and troglitazone were mediated by PPARγ activation.

In summary, PPARγ activation in MCs leads to beneficial effects for TGF-β-associated glomerulosclerosis. These renoprotective effects combine to suppress the activation of MCs and ECM accumulation. The relevant regulation mechanisms act through the suppression of PKA signaling, which is tightly associated with TGF-β. Our study thus suggests a novel inhibition of PKA signaling that is mediated by PPARγ activation, and explores the role of the renoprotective mechanisms induced by PPARγ agonists. This pathway will provide an additional therapeutic approach for the treatment of TGF-β-mediated glomerulosclerosis.

Figure 5. PPARγ ligands inhibit the activation of MCs mediated by TGF-β1. The expression of αSMA mediated by TGF-β1 was measured by Western blot. MCs were treated with troglitazone (5 μmol/L), telmisartan (10 μmol/L) or H89 (20 μmol/L) after exposure to TGF-β1. *P<0.05 vs TGF-β1 treated group. n=3.

Figure 6. PPARγ agonists inhibited the collagen IV accumulation. (A) The expression levels of collagen IV were measured by Western blot. MCs were treated with troglitazone (5 μmol/L), telmisartan (10 μmol/L) or H89 (20 μmol/L) after exposure to TGF-β1. *P<0.05 vs TGF-β1 treated group, n=3. (B–F) The localization of collagen IV in MCs was shown by confocal laser scanning microscopy. (B) Normal group; (C) TGF-β1-treated group (2 ng/mL); (D) Troglitazone (5 μmol/L) with TGF-β1; (E) Telmisartan (10 μmol/L) with TGF-β1; (F) H89 (20 μmol/L) with TGF-β1.
Acknowledgements
This project was supported by the National Natural Science Foundation of China (No 30672227; 30571950; 30600667; 30700895; 30628029; 30770913).

Author contribution
Ying Yao designed research; Rong Zou performed research; Gang Xu, Xiao-cheng Liu, Min Han, Jing-jing Jiang, Qian Huang, and Yong He contributed new analytical tools and reagents; Rong Zou and Ying Yao analyzed data; Rong Zou wrote the paper.

References
1. Daskalakis N, Winn MP. Focal and segmental glomerulosclerosis. Cell Mol Life Sci 2006; 63: 2506–11.
2. Padiyar A, Sedor JR. Genetic and genomic approaches to glomerulosclerosis. Curr Mol Med 2005; 5: 497–507.
3. Cybulsky AV. Growth factor pathways in proliferative glomerulonephritis. Curr Opin Nephrol Hypertens 2009; 20: 217–23.
4. Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 2003; 23: 532–43.
5. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1: 169–78.
6. Li MO, Wan Y, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99–146.
7. Prud’homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87: 1077–91.
8. Zhang L, Duan CJ, Binkley C, Li G, Uhler MD, Logsdon CD, et al. A transforming growth factor beta-induced Smad3/Smad4 complex directly activates protein kinase A. Mol Cell Biol 2004; 24: 2169–80.
9. Singh LP, Green K, Alexander M, Bassly S, Crook ED. Hexosamines and TGF-beta1 use similar signaling pathways to mediate matrix protein synthesis in mesangial cells. Am J Physiol Renal Physiol 2004; 286: F409–16.
10. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 2007; 99: 27–40.
11. Sharma AM, Staels B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue–understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92: 386–95.
12. Spears M, Mcsharry C, Thomson NC. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 2006; 36: 1494–504.
13. Guyton K, Bond R, Reilly C, Gilkeson G, Halushka P, Cook J. Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation. J Leukoc Biol 2001; 69: 631–8.
14. Zheng F, Fornoni A, Elliot SJ, Guan Y, Breyer MD, Striker LJ, et al. Uptregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPAR-gamma activation. Am J Physiol Renal Physiol 2002; 282: F639–48.
15. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, et al. Anti-inflammatory, antiproliferative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003; 108: 2805–11.
16. Iglesias P, Diez J J. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006; 154: 613–21.
17. Forman BM, Tontonz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 803–12.
18. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46: 1319–27.
19. Lennon AM, Ramaqué M, Dessouroy A, Pierre M. MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-delta(12,14)-prostaglandin J2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species. J Biol Chem 2002; 277: 29681–5.
20. Debril MB, Renaud JP, Fajas L, Auwex J. The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med 2001; 79: 39–40.
21. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899–910.
22. Yang HC, Ma LJ, Ma J, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006; 69: 1756–64.
23. Tamaki H. Glucose-stimulated cAMP-protein kinase A pathway in yeast Saccharomyces cerevisiae. J Biosci Bioeng 2007; 104: 245–50.
24. Dalton GD, Dewey WL. Protein kinase inhibitor peptide (PKI): a family of endogenous neuropeptides that modulate neuronal cAMP-dependent protein kinase function. Neuropeptides 2006; 40: 23–34.
25. Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, Seger R. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol 2007; 27: 803–17.
26. Gao Z, He Q, Beng B, Chiao PJ, Ye J. Regulation of nuclear transllocation of HDAC3 by IkappaBalpha is required for tumor necrosis factor inhibition of peroxisome proliferator-activated receptor gamma function. J Biol Chem 2006; 281: 4540–7.
27. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005; 19: 2783–810.
28. Liao JH, Chen JS, Chai MQ, Zhao S, Song JG. The involvement of p38 MAPK in transforming growth factor beta1-induced apoptosis in murine hepatocytes. Cell Res 2001; 11: 89–94.
29. Zhang Y, Derynck R. Transcriptional regulation of the transforming growth factor-beta-inducible mouse germ line Ig alpha constant region gene by functional cooperation of Smad, CReB, and AML family members. J Biol Chem 2000; 275: 16797–85.
30. Liu G, Ding W, Neiman J, Mulder KM. Requirement of Smad3 and CReB-1 in mediating transforming growth factor-beta (TGF beta) induction of TGF beta 3 secretion. J Biol Chem 2006; 281: 29479–90.
31. Singh LP, Green K, Alexander M, Bassly S, Crook ED. Hexosamines and TGF-beta1 use similar signaling pathways to mediate matrix protein synthesis in mesangial cells. Am J Physiol Renal Physiol 2004; 286: F409–16.
32. Han S, Ritzenthaler JD, Rivera HN, Roman J. Requirement of Smad3 and CReB and Sp1. Am J Physiol Lung Cell Mol Physiol 2005; 289: 419–28.
33. Shabb J B. Physiological substrates of cAMP-dependent protein kinase. Chem Rev 2001; 101: 2381–411.